Advertisement
News
Advertisement

Company Attends TSX Venture 50 Spotlight Event and Provides Operational Update

Tue, 04/03/2012 - 5:45am
The Associated Press

(http://www.verisante.com/)

Verisante Technology, Inc.(http://www.verisante.com/) (TSX

VENTURE:VRS)(OTCQX:VRSEF)(PINKSHEETS:VRSEF)(FRANKFURT:V3T) (the

"Company" or "Verisante"), a leader in cancer detection technology,

announced today that president & CEO Thomas Braun will participate in

the opening of the

market(http://www.tmx.com/en/news_events/broadcast_centre/events_calendar.html)

on Tuesday April 3 in honour of Verisante being named the top ranking

Technology and Life Sciences Company on the TSX Venture Top 50.

The TSX Venture Exchange's annual list of its top 50 emerging publicly

traded companies is a ranking of the strongest performers from five

industry sectors. Verisante ranked number one on the list of top 10

leading Technology and Life Sciences companies for the year. Companies

are selected based on four equally weighted criteria - return on

investment, trading activity, market capitalization growth, and

analyst coverage. The results were obtained from data to December 31,

2011.

In addition, Mr. Braun will be speaking at the TSX Venture 50

Spotlight event in Toronto to an audience comprised of portfolio

managers, investment bankers, research analysts and investment

advisors.

"The TSX Venture 50 Spotlight event comes at a very opportune time for

the Company," said Braun. "With our Canadian distributor now in place

and the Aura's clinical study results being published in Cancer

Research, we are looking forward to providing this life-saving

technology to medical professionals in Canada, Europe and Australia,

where Aura is currently approved for sale."

Ten beta Verisante Aura systems will be completed, tested and placed

for field testing in April, with manufacturing and production set to

begin in the second half of the year.

Verisante Aura is a non-invasive optical system designed as a tool to

aid medical professionals in the assessment of suspect skin lesions

for diagnosis as either skin cancer or a benign disorder. It uses

Raman spectroscopy to biochemically analyze the skin, providing

immediate results.

Aura is indicated for use for the evaluation of skin lesions that may

be clinically suspicious for melanoma, squamous cell carcinoma, basal

cell carcinoma, and/or actinic keratosis when a medical professional

chooses to obtain additional information to rule out one of the above

conditions before making a final decision to biopsy. The device will

help to automate the current process of diagnosis, allowing rapid

scanning of the 20 to 40 skin lesions on at-risk individuals,

improving patient outcomes and comfort.

Verisante Aura was recently awarded Popular Science Magazine's "Best

of What's New

Award(http://www.popsci.com/bown/2011/product/verisante-aura)" for

2011, and Verisante Core was named one of the top 10 cancer

breakthroughs(http://verisante.com/news/72/canadian-cancer-society-names-verisante-core-a-top-10-cancer-breakthrough-of-2011-/)

of 2011 by the Canadian Cancer Society. In addition, the Company was

named a finalist for the 2011 Regional Awards for New

Technology(http://cme-mec.ca/?actionshow&lidJCKNC-E742G-1W6JA&cid39A7P-BQXJT-NYWII&comactionshow)

by the Canadian Manufacturers & Exporters and the National Research

Council of Canada.

About Verisante Technology, Inc.

Verisante is a medical device company(http://www.verisante.com/about/)

committed to commercializing innovative systems for the early

detection of cancer(http://www.verisante.com/). The Verisante Aura

for skin cancer detection(http://www.verisante.com/products/aura/) and

the Verisante Core series for lung, colon and cervical cancer

detection(http://www.verisante.com/products/core/) utilize a

proprietary cancer detection platform while the operating software and

probe technology are unique to each device. The cancer detection

platform was developed by the BC Cancer Agency and tested and refined

at the Skin Care Centre at Vancouver General Hospital. This exclusive

platform technology allows Verisante to develop and offer a range of

compact, non-invasive cancer detection devices that offer physicians

immediate results(http://www.verisante.com/products/aura/) for many of

the most common cancers. The Aura has been approved for sale in

Canada, Europe and Australia. The Core has not yet been approved for

sale.

Forward-Looking Statements

This release contains forward-looking statements, including, but not

limited to, statements regarding the future commercialization of

medical devices, the market demand for these products and the

proprietary protections the Company will obtain with regard to the

technology, all of which statements are subject to market risks, and

the possibility that the Company will not be able to obtain patent

protection or obtain sufficient customer demand. These statements are

made based upon current expectations and actual results may differ

from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the

contents of this press release. Neither the TSX Venture Exchange nor

its Regulation Services Provider (as that term is defined in the

policies of the TSX Venture Exchange) accepts responsibility for the

adequacy or accuracy of this press release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading